Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis

被引:82
作者
Hwang, S. M. [1 ,2 ]
Kim, D. D. [1 ]
Chung, S. J. [1 ]
Shim, C. K. [1 ,2 ]
机构
[1] Seoul Natl Univ, Coll Pharm, Dept Pharmaceut, Seoul 151742, South Korea
[2] Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Natl Res Lab Transporters Targeted Drug Design, Seoul 151742, South Korea
关键词
hyaluronan microspheres; ofloxacin; tuberculosis lung; alveolar macrophage;
D O I
10.1016/j.jconrel.2008.04.009
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Microspheres containing ofloxacin (HMO) with a mean diameter of 2-5 mu m were prepared by the co-spray drying of ofloxacin and the sodium salt of hyaluronic acid (hyaluronan). Recovery of lactose blends of HMO from stage 11 of the twin-stage impinger (TSI) reached 43%, indicating favorable delivery of the drug to the lung via inhalation. The area under the ofloxacin concentration curve from time zero to infinity (AUC) was estimated for plasma and lungs in rats following intratracheal (it), intravenous (iv), and oral (po) administration of HMO, ofloxacin microspheres (MO), and an aqueous solution of ofloxacin (OS), at an equivalent ofloxacin dose of 8 mg/kg rat. The AUC ratio between the lung and plasma for it-administered HMO was 10.9-, 9.3- and 1.8-fold greater than iv OS, po OS, and it MO, respectively, suggesting that the most efficient delivery of ofloxacin to the lung is feasible via HMO. Moreover, in vitro uptake of ofloxacin from HMO by air-surface cultured alveolar macrophages (RAW 264.7) was 2.1- and 1.7-fold higher than ofloxacin uptake from OS and MO (P < 0.05). Taken together, the results of the present study demonstrate that pulmonary administration of ofloxacin via HMO would improve the treatment efficacy of ofloxacin against tuberculosis, compared to other forms of ofloxacin (OS and MO) and to other routes of administration (iv and po). (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:100 / 106
页数:7
相关论文
共 40 条
[1]  
ALLEN LA, 2005, ANSELS PHARM DOSAGE, V8, P195
[2]   OZONE STIMULATES SYNTHESIS OF INFLAMMATORY CYTOKINES BY ALVEOLAR MACROPHAGES IN-VITRO [J].
ARSALANE, K ;
GOSSET, P ;
VANHEE, D ;
VOISIN, C ;
HAMID, Q ;
TONNEL, AB ;
WALLAERT, B .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1995, 13 (01) :60-68
[3]  
Baruah Himangshu, 2004, J Vet Sci, V5, P97
[4]   USE OF LIPOSOME PREPARATION TO TREAT MYCOBACTERIAL INFECTIONS [J].
BERMUDEZ, LE .
IMMUNOBIOLOGY, 1994, 191 (4-5) :578-583
[5]   LONG-TERM SAFETY OF OFLOXACIN AND CIPROFLOXACIN IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS [J].
BERNING, SE ;
MADSEN, L ;
ISEMAN, MD ;
PELOQUIN, CA .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 151 (06) :2006-2009
[6]   Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin [J].
Brown, MB ;
Jones, SA .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2005, 19 (03) :308-318
[7]   Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema? [J].
Cantor, JO ;
Turino, GM .
CHEST, 2004, 125 (01) :288-292
[8]  
CAZIN M, 1988, METHOD FIND EXP CLIN, V10, P231
[9]  
CAZIN M, 1990, EUR RESPIR J, V3, P1015
[10]   CRITICAL EVALUATION OF THE POTENTIAL ERROR IN PHARMACOKINETIC STUDIES OF USING THE LINEAR TRAPEZOIDAL RULE METHOD FOR THE CALCULATION OF THE AREA UNDER THE PLASMA LEVEL TIME CURVE [J].
CHIOU, WL .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1978, 6 (06) :539-546